Egypt
· Delayed Price · Currency is EGP Ibnsina Pharma Statistics
Total Valuation
Ibnsina Pharma has a market cap or net worth of EGP 9.55 billion. The enterprise value is 29.97 billion.
| Market Cap | 9.55B |
| Enterprise Value | 29.97B |
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ibnsina Pharma has 1.01 billion shares outstanding.
| Current Share Class | 1.01B |
| Shares Outstanding | 1.01B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.01% |
| Owned by Institutions (%) | 23.67% |
| Float | 652.98M |
Valuation Ratios
The trailing PE ratio is 16.88 and the forward PE ratio is 8.41. Ibnsina Pharma's PEG ratio is 0.19.
| PE Ratio | 16.88 |
| Forward PE | 8.41 |
| PS Ratio | 0.15 |
| PB Ratio | 4.38 |
| P/TBV Ratio | 4.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.19 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.15, with an EV/FCF ratio of -13.05.
| EV / Earnings | 52.99 |
| EV / Sales | 0.48 |
| EV / EBITDA | 10.15 |
| EV / EBIT | 11.14 |
| EV / FCF | -13.05 |
Financial Position
The company has a current ratio of 1.00, with a Debt / Equity ratio of 10.05.
| Current Ratio | 1.00 |
| Quick Ratio | 0.67 |
| Debt / Equity | 10.05 |
| Debt / EBITDA | 7.41 |
| Debt / FCF | -9.53 |
| Interest Coverage | 1.34 |
Financial Efficiency
Return on equity (ROE) is 37.50% and return on invested capital (ROIC) is 8.54%.
| Return on Equity (ROE) | 37.50% |
| Return on Assets (ROA) | 6.31% |
| Return on Invested Capital (ROIC) | 8.54% |
| Return on Capital Employed (ROCE) | 80.36% |
| Revenue Per Employee | 11.33M |
| Profits Per Employee | 102,841 |
| Employee Count | 5,500 |
| Asset Turnover | 2.34 |
| Inventory Turnover | 9.23 |
Taxes
In the past 12 months, Ibnsina Pharma has paid 74.36 million in taxes.
| Income Tax | 74.36M |
| Effective Tax Rate | 9.62% |
Stock Price Statistics
The stock price has increased by +237.01% in the last 52 weeks. The beta is 0.40, so Ibnsina Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | +237.01% |
| 50-Day Moving Average | 9.18 |
| 200-Day Moving Average | 6.86 |
| Relative Strength Index (RSI) | 58.27 |
| Average Volume (20 Days) | 5,730,401 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ibnsina Pharma had revenue of EGP 62.31 billion and earned 565.62 million in profits. Earnings per share was 0.56.
| Revenue | 62.31B |
| Gross Profit | 5.05B |
| Operating Income | 2.69B |
| Pretax Income | 772.66M |
| Net Income | 565.62M |
| EBITDA | 2.83B |
| EBIT | 2.69B |
| Earnings Per Share (EPS) | 0.56 |
Balance Sheet
The company has 1.46 billion in cash and 21.89 billion in debt, giving a net cash position of -20.43 billion or -20.27 per share.
| Cash & Cash Equivalents | 1.46B |
| Total Debt | 21.89B |
| Net Cash | -20.43B |
| Net Cash Per Share | -20.27 |
| Equity (Book Value) | 2.18B |
| Book Value Per Share | 2.16 |
| Working Capital | 87.69M |
Cash Flow
In the last 12 months, operating cash flow was -2.04 billion and capital expenditures -253.74 million, giving a free cash flow of -2.30 billion.
| Operating Cash Flow | -2.04B |
| Capital Expenditures | -253.74M |
| Free Cash Flow | -2.30B |
| FCF Per Share | -2.28 |
Margins
Gross margin is 8.10%, with operating and profit margins of 4.32% and 1.12%.
| Gross Margin | 8.10% |
| Operating Margin | 4.32% |
| Pretax Margin | 1.24% |
| Profit Margin | 1.12% |
| EBITDA Margin | 4.54% |
| EBIT Margin | 4.32% |
| FCF Margin | n/a |
Dividends & Yields
Ibnsina Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.17% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 5.93% |
| FCF Yield | -24.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.16666.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.16666 |
Scores
Ibnsina Pharma has an Altman Z-Score of 2.36 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.36 |
| Piotroski F-Score | 5 |